[A19-39] Dacomitinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2019
Commission awarded on 29.04.2019 by the Federal Joint Committee (G-BA).
Adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations
Patients with L858R or Del19 mutations: Advantages in overall survival and individual side effects are offset by numerous disadvantages in several outcome categories. Other mutations: No data available. Added benefit not proven for either of both research questions.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.